Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer ...

Belzutifan-lenvatinib slows progression versus cabozantinib with much longer response dura ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...

Built on Insights from Patients and Caregivers, the New Website Curates Trusted Resources from Leading Organizations in Kidney Cancer NUTLEY, N.J., Feb. 26, 2026 /PRNewswire/ -- Eisai Inc. announced ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...

Add Yahoo as a preferred source to see more of our stories on Google. On the list of medical terms we’d rather never hear, cancer is at the top. But when it comes to fighting it, knowledge is ...

Eisai has a position in kidney cancer with Lenvima (lenvatinib), a kinase inhibitor that is approved for use in combination ...

The lead singer of the band 3 Doors Down shared Wednesday that he has stage 4 kidney cancer that has spread to his lung. In an Instagram video, Brad Arnold said he had been feeling sick for a few ...